Abstract
Metastasis is the chief cause of mortality from cancer, but the mechanisms leading to metastasis are poorly understood. We used a proteomics approach to screen for metastasis-associated proteins and found that collapsin response mediator protein-4 (CRMP4) expression was inversely associated with the lymph node metastasis of prostate cancer (PCa). Subsequent in vitro and in vivo studies revealed that overexpression of CRMP4 not only suppressed the invasion ability of PCa cells, but also strongly inhibited tumor metastasis in an animal model. Furthermore, methylation of a CpG island within the promoter region of the CRMP4 gene is responsible for downregulation of CRMP4 expression. Thus, in this study, we show new function of CRMP4 as a metastasis-suppressor in PCa. The findings provide new mechanistic insights into metastasis and therapeutic potential for this most common male cancer.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Accession codes
Abbreviations
- 2D:
-
two-dimensional
- BPH:
-
benign prostate hyperplasia
- CRMP:
-
collapsin response mediator protein
- DIGE:
-
fluorescence difference gel electrophoresis
- EGFP:
-
enhanced green fluorescent protein
- GAPDH:
-
glyceraldehyde 3-phosphate dehydrogenase
- IHC:
-
immunohistochemistry
- LNM:
-
lymph node metastasis
- MSP:
-
methylation specific PCR
- PCa:
-
prostate cancer
- VEGF:
-
vascular endothelial growth factor
References
Arimura N, Inagaki N, Chihara K, Ménager C, Nakamura N, Amano M et al. (2000). Phosphorylation of collapsin response mediator protein-2 by Rho-kinase. Evidence for two separate signaling pathways for growth cone collapse. J Biol Chem 275: 23973–23980.
Brandes JC, Carraway H, Herman JG . (2007). Optimal primer design using the novel primer design program: MSP primer provides accurate methylation analysis of the ATM promoter. Oncogene 26: 6229–6237.
Burton JB, Johnson M, Sato M, Koh SB, Mulholland DJ, Stout D et al. (2008). Adenovirus-mediated gene expression imaging to directly detect sentinel lymph node metastasis of prostate cancer. Nat Med 14: 882–888.
Cai CQ, Peng Y, Buckley MT, Wei J, Chen F, Liebes L et al. (2008). Epidermal growth factor receptor activation in prostate cancer by three novel missense mutations. Oncogene 27: 3201–3210.
Cathcart MC, Tamosiuniene R, Chen G, Neilan TG, Bradford A, O'Byrne KJ et al. (2008). Cyclooxygenase-2-Linked attenuation of hypoxia-induced pulmonary hypertension and intravascular thrombosis. J Pharmacol Exp Ther 326: 51–58.
Chi AS, Sorensen AG, Jain RK, Batchelor TT . (2009). Angiogenesis as a therapeutic target in malignant gliomas. Oncologist 14: 621–636.
Clark SJ, Harrison J, Paul CL, Frommer M . (1994). High sensitivity mapping of methylated cytosines. Nucleic Acids Res 22: 2990–2997.
de Boer M, van Deurzen CH, van Dijck JA, Borm GF, van Diest PJ, Adang EM et al. (2009). Micrometastases or isolated tumor cells and the outcome of breast cancer. N Engl J Med 361: 653–663.
Deo RC, Schmidt EF, Elhabazi A, Togashi H, Burley SK, Strittmatter SM . (2004). Structural bases for CRMP function in plexin-dependent semaphorin 3A signaling. EMBO J 23: 9–22.
Feinberg AP, Ohlsson R, Henikoff S . (2006). The epigenetic progenitor origin of humancancer. Nat Rev Genet 7: 21–33.
Fu H, Li W, Liu Y, Lao Y, Liu W, Chen C et al. (2007). Mitochondrial proteomic analysis and characterization of the intracellular mechanisms of bis(7)-tacrine in protecting against glutamate-induced excitotoxicity in primary cultured neurons. J Proteome Res 6: 2435–2446.
Fukada M, Watakabe I, Yuasa-Kawada J, Kawachi H, Kuroiwa A, Matsuda Y et al. (2000). Molecular characterization of CRMP5, a novel member of the collapsin response mediator protein family. J Biol Chem 275: 37957–37965.
Gaetano C, Matsuo T, Thiele CJ . (1997). Identification and characterization of a retinoic acidregulated human homologue of the unc-33-like phosphoprotein (hUlip) from neuroblastoma cells. J Biol Chem 272: 12195–12201.
Görg A, Weiss W, Dunn MJ . (2004). Current two-dimensional electrophoresis technology for proteomics. Proteomics 4: 3665–3685.
Goshima Y, Nakamura F, Strittmatter P, Strittmatter SM . (1995). Collapsin-induced growth cone collapse mediated by an intracellular protein related to UNC-33. Nature 376: 509–514.
Hanash S . (2003). Disease proteomics. Nature 422: 226–232.
Herman JG, Graff JR, Myöhänen S, Nelkin BD, Baylin SB . (1996). Methylation specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93: 9821–9826.
Jackson D, Rowlinson RA, Eaton CK, Nickson JA, Wilson ID, Mills JD et al. (2006). Prostatic tissue protein alterations due to delayed time to freezing. Proteomics 6: 3901–3908.
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T et al. (2008). Cancer statistics, 2008. CA Cancer J Clin 58: 71–96.
Kishimoto H, Kojima T, Watanabe Y, Kagawa S, Fujiwara T, Uno F et al. (2006). in vivo imaging of lymph node metastasis with telomerase-specific replication-selective adenovirus. Nat Med 12: 1213–1219.
Klein CA . (2008). Cancer: the metastasis cascade. Science 321: 1785–1787.
Lapointe J, Li C, Higgins JP, van de Rijn M, Bair E, Montgomery K et al. (2004). Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci USA 101: 811–816.
Li LC, Dahiya R . (2002). MethPrimer: designing primers for methylation PCRs. Bioinformatics 18: 1427–1431.
Loberg RD, Logothetis CJ, Keller ET, Pienta KJ . (2005). Pathogenesis and treatment of prostate cancer bone metastases: targeting the lethal phenotype. J Clin Oncol 23: 8232–8241.
Matsuo T, Stauffer JK, Walker RL, Meltzer P, Thiele CJ . (2000). Structure and promoter analysis of the human unc-33-like phosphoprotein gene. E-box required for maximal expression in neuroblastoma and myoblasts. J Biol Chem 275: 16560–16568.
Miao HQ, Soker S, Feiner L, Alonso JL, Raper JA, Klagsbrun M . (1999). Neuropilin-1 mediates collapsin-1/semaphorin III inhibition of endothelial cell motility: functional competition of collapsin-1 and vascular endothelial growth factor-165. J Cell Biol 146: 233–242.
Miyake H, Hara I, Kurahashi T, Inoue TA, Eto H, Fujisawa M . (2007). Quantitative detection of micrometastases in pelvic lymph nodes in patients with clinically localized prostate cancer by real-time reverse transcriptase -PCR. Clin Cancer Res 13: 1192–1197.
Ozanne BW, Spence HJ, McGarry LC, Hennigan RF . (2007). Transcription factors control invasion: AP-1 the first among equals. Oncogene 26: 1–10.
Paris PL, Andaya A, Fridlyand J, Jain AN, Weinberg V, Kowbel D et al. 2004. Whole genome scanning identifies genotypes associated with recurrence and metastasis in prostate tumors. Hum Mol Genet 13: 1303–1313.
Rinker-Schaeffer CW, O′Keefe JP, Welch DR, Theodorescu D . (2006). Metastasis suppressor proteins: discovery, molecular mechanisms, and clinical application. Clin Cancer Res 12: 3882–3889.
Rosslenbroich V, Dai L, Baader SL, Noegel AA, Gieselmann V, Kappler J . (2005). Collapsin response mediator protein-4 regulates F-actin bundling. Exp Cell Res 310: 434–444.
Schewe DM, Biller T, Maurer G, Asangani IA, Leupold JH, Lengyel ER et al. (2005). Combination analysis of activator protein-1 family members, Sp1 and an activator protein-2alpha-related factor binding to different regions of the urokinase receptor gene in resected colorectal cancers. Clin Cancer Res 11: 8538–8548.
Seth A, Watson DK . (2005). ETS transcription factors and their emerging roles in human cancer. Eur J Cancer 41: 2462–2478.
Shaffer DR, Pandolfi PP . (2006). Breaking the rules of cancer. Nat Med 12: 14–15.
Shih JY, Lee YC, Yang SC, Hong TM, Huang CY, Yang PC . (2003). Collapsin response mediator protein-1: a novel invasion-suppressor gene. Clin Exp Metastasis 20: 69–76.
Shih JY, Yang SC, Hong TM, Yuan A, Chen JJ, Yu CJ et al. (2001). Collapsin response mediator protein-1 and the invasion and metastasis of cancer cells. J Natl Cancer Inst 93: 1392–1400.
Singh LS, Berk M, Oates R, Zhao Z, Tan H, Jiang Y et al. (2007). Ovarian cancer G protein-coupled receptor 1, a new metastasis suppressor gene in prostate cancer. J Natl Cancer Inst 99: 1313–1327.
Steeg PS . (2003). Metastasis suppressors alter the signal transduction of cancer cells. Nat Rev Cancer 3: 55–63.
Steeg PS . (2006). Tumor metastasis: mechanistic insights and clinical challenges. Nat Med 12: 895–904.
Tate PH, Bird AP . (1993). Effects of DNA methylation on DNA-binding proteins and gene expression. Curr Opin Genet Dev 3: 226–231.
Ting AH, McGarvey KM, Baylin SB . (2006). The cancer epigenome-components and functional correlates. Genes Dev 20: 3215–3231.
Tomlins SA, Laxman B, Dhanasekaran SM, Helgeson BE, Cao X, Morris DS et al. (2007). Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature 448: 595–599.
Uzawa K, Ono K, Suzuki H, Tanaka C, Yakushiji T, Yamamoto N et al. (2002). High prevalence of decreased expression of KAI1 metastasis suppressor in human oral carcinogenesis. Clin Cancer Res 8: 828–835.
Wang LH, Strittmatter SM . (1997). Brain CRMP forms heterotetramers similar to liver dihydropyrimidinase. J Neurochem 69: 2261–2269.
Yacoub M, Coulon A, Celhay O, Irani J, Cussenot O, Fromont G . (2009). Differential expression of the semaphorin 3A pathway in prostatic cancer. Histopathology 55: 392–398.
Yang D, Koupenova M, McCrann DJ, Kopeikina KJ, Kagan HM, Schreiber BM et al. (2008). The A2b adenosine receptor protects against vascular injury. Proc Natl Acad Sci USA 105: 792–796.
Zilberman D . (2007). The human promoter methylome. Nat Genet 39: 442–443.
Acknowledgements
We thank Professor Quentin Liu (State Key Laboratory of Oncology in South China, Cancer Center, Sun Yat-Sen University) for providing excellent technical assistances. Special thanks to Professor Zhou Zhu (Johns Hopkins University, School of Medicine, USA) for valuable suggestions and critical reading of this paper. This work was supported by Chinese National Natural Science Foundation 30772178, 30973011, 30901496, Key Project of Guangdong Provincial Science and Technology Research 7117362, Key Project of Chinese Ministry of Health and Chinese National Hi-Tech Research and Development Program 2007AA021906.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies the paper on the Oncogene website
Supplementary information
Rights and permissions
About this article
Cite this article
Gao, X., Pang, J., Li, LY. et al. Expression profiling identifies new function of collapsin response mediator protein 4 as a metastasis-suppressor in prostate cancer. Oncogene 29, 4555–4566 (2010). https://doi.org/10.1038/onc.2010.213
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2010.213
Keywords
This article is cited by
-
CircSCAF8 promotes growth and metastasis of prostate cancer through the circSCAF8-miR-140-3p/miR-335-LIF pathway
Cell Death & Disease (2022)
-
M6A methylation of DEGS2, a key ceramide-synthesizing enzyme, is involved in colorectal cancer progression through ceramide synthesis
Oncogene (2021)
-
Diabetes, an independent poor prognostic factor of non-B non-C hepatocellular carcinoma, correlates with dihydropyrimidinase-like 3 promoter methylation
Scientific Reports (2020)
-
Inhibition of cell-adhesion protein DPYSL3 promotes metastasis of lung cancer
Respiratory Research (2018)
-
Collapsin response mediator protein 4 promotor methylation level as a potential predictor for diagnosing primary malignant lymphoma of the prostate
Cancer Cell International (2018)